Brief: Spero Therapeutics Announces Fourth Quarter And Full Year 2022 Operating Results And Provides Business Update
30/03/2023 21:35
March 30 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR
2022
OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
* SPERO THERAPEUTICS INC - CASH AND CASH EQUIVALENTS,
NON-DILUTIVE
FUNDING COMMITMENTS SUFFICIENT TO FUND EXPENSES & CAP EX
REQUIREMENTS BEYOND 2024
Source text for Eikon: ID:nGNX7SPFSb
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)